Patients with haemophilia can now look forward to greater life expectancy than ever before--a development that can be attributed to improved healthcare strategies and more effective treatments. In the last few decades, the treatment of haemophilia patients with inhibitors has also witnessed dramatic improvements through the development of bypassing agents, including recombinant activated factor VII (rFVIIa, NovoSeven; Novo Nordisk, Bagsvaerd, Denmark). Growing evidence suggests that early initiation of treatment with rFVIIa results in greater haemostatic efficacy with fewer doses, leading to improved overall outcome. The new NovoSeven room temperature stable formulation has been designed to optimize on-demand treatment by facilitating early initiation of therapy for haemorrhagic episodes, which brings the potential benefits of faster bleed resolution, reduced frequency of re-bleeding and reduced product consumption. This is particularly important for inhibitor patients, in whom orthopaedic complications are more severe than in non-inhibitor patients. Early treatment might help improve musculoskeletal status and therefore reduce disability, which improves patient quality of life and aids integration into society. These clinical advantages are also accompanied by both short-term and long-term economic benefits. NovoSeven room temperature stable might also improve patient compliance and treatment convenience, as patients can carry their treatment with them and administer it wherever they are, without being restricted by the need for a refrigerator and without the need to visit a hospital or to return home. The potential benefits of NovoSeven room temperature stable make this new formulation a valuable addition to our armamentarium in the ongoing effort to improve haemophilia care.